Oncotarget

Research Papers:

Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner

Dimiter B. Avtanski, Arumugam Nagalingam, Panjamurthy Kuppusamy, Michael Y. Bonner, Jack L. Arbiser, Neeraj K. Saxena and Dipali Sharma _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:16396-16410. https://doi.org/10.18632/oncotarget.3844

Metrics: PDF 1365 views  |   HTML 1761 views  |   ?  


Abstract

Dimiter B. Avtanski1, Arumugam Nagalingam1,*, Panjamurthy Kuppusamy2, Michael Y. Bonner3, Jack L. Arbiser3,4, Neeraj K. Saxena2 and Dipali Sharma1

1 Department of Oncology, Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

2 Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

3 Department of Dermatology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA

4 Atlanta Veterans Administration Medical Center, Atlanta, GA, USA

* Co-first author

Correspondence to:

Dipali Sharma, email:

Neeraj Saxena, email:

Keywords: honokiol, leptin, miR-34a, breast cancer

Received: January 20, 2015 Accepted: March 20,2015 Published: April 15, 2015

Abstract

Obesity greatly influences risk, progression and prognosis of breast cancer. As molecular effects of obesity are largely mediated by adipocytokine leptin, finding effective novel strategies to antagonize neoplastic effects of leptin is desirable to disrupt obesity-cancer axis. Present study is designed to test the efficacy of honokiol (HNK), a bioactive polyphenol from Magnolia grandiflora, against oncogenic actions of leptin and systematically elucidate the underlying mechanisms. Our results show that HNK significantly inhibits leptin-induced breast-cancer cell-growth, invasion, migration and leptin-induced breast-tumor-xenograft growth. Using a phospho-kinase screening array, we discover that HNK inhibits phosphorylation and activation of key molecules of leptin-signaling-network. Specifically, HNK inhibits leptin-induced Wnt1-MTA1-β-catenin signaling in vitro and in vivo. Finally, an integral role of miR-34a in HNK-mediated inhibition of Wnt1-MTA1-β-catenin axis was discovered. HNK inhibits Stat3 phosphorylation, abrogates its recruitment to miR-34a promoter and this release of repressor-Stat3 results in miR-34a activation leading to Wnt1-MTA1-β-catenin inhibition. Accordingly, HNK treatment inhibited breast tumor growth in diet-induced-obese mouse model (exhibiting high leptin levels) in a manner associated with activation of miR-34a and inhibition of MTA1-β-catenin. These data provide first in vitro and in vivo evidence for the leptin-antagonist potential of HNK revealing a crosstalk between HNK and miR34a and Wnt1-MTA1-β-catenin axis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3844